About

Valluvan Jeevanandam, MD, is the Cynthia Chow Professor of Surgery at the University of Chicago Department of Surgery. His clinical interests include artificial hearts, bloodless heart surgery, heart failure, heart transplant, minimally invasive cardiac surgery, valve disease, valvuloplasty, and ventricular assist devices (VADs). Dr. Jeevanandam has contributed to the field through research on bloodless heart transplantation in patients who refuse transfusion, as well as the surgical management of acute myocardial infarction and associated complications. His work also encompasses mechanisms of cardiac electronic device interference with the tricuspid valve, innovative approaches to aortic repair in patients refusing blood transfusion, and strategies to mitigate post-operative right ventricular dysfunction after VAD implantation. Additionally, he has been involved in complex transplant procedures, including combined heart and liver transplants, and studies on the outcomes of ambulatory counter pulsation devices as a bridge to heart transplantation. Dr. Jeevanandam's research and clinical expertise focus on advancing surgical techniques and improving outcomes for patients with severe cardiac conditions.

Research topics

• Medicine
• Internal medicine
• Surgery
• Cardiology
• Computer Science
• Computer Security
• Intensive care medicine
• Anesthesia
• Family medicine
• Endocrinology
• Risk analysis (engineering)
• Nursing
• Pathology
• Medical emergency

Selected publications

• Stellate Ganglion Block as a Therapeutic Option for Refractory Ventricular Tachycardia Post-Left Ventricular Assist Device Implantation: A Case Series

  The Journal of Heart and Lung Transplantation · 2025-04-01

  article
  PublisherDOI

• CULTURE NEGATIVE ENDOCARDITIS: A CASE REPORT OF HISTOPLASMA CAPSULATUM ENDOCARDITIS

  Journal of the American College of Cardiology · 2025-03-29

  article
  PublisherDOI

• Mechanisms of Cardiac Implantable Electronic Device Interference With the Tricuspid Valve Apparatus

  The American Journal of Cardiology · 2025-04-23

  article
  PublisherDOI

• Bloodless heart transplantation in patients who refuse transfusion: An 11-year case series

  Journal of Thoracic and Cardiovascular Surgery · 2025-09-10 · 1 citations

  articleSenior author
  PublisherDOI

• Reduced Density of Commensal Gut Microbial Species is Associated with Post Heart Transplant Infection

  The Journal of Heart and Lung Transplantation · 2025-04-01

  articleOpen access
  PublisherOA PDFDOI

• Two-staged aortic repair for acute type A aortic dissection in patients refusing blood transfusion

  Vascular · 2025-02-17 · 1 citations

  articleSenior authorCorresponding

  Background It is still challenging to perform high-risk cases, such as acute type A dissection, which frequently require blood transfusions. We created perioperative bloodless protocol, but it includes an optimization to increase the preoperative hemoglobin level enough to tolerate cardiopulmonary bypass. However, it would be impossible to optimize such patients using the strategy in the setting of emergent surgery. We sought to create a surgical strategy in an effort to reduce blood loss for acute type A dissection patients refusing blood transfusion. Methods We reviewed the records of two patients in our aortic surgery database who presented with acute aortic dissection and refused blood transfusion. These patients underwent two-staged aortic repair with ascending aortic replacement with debranching to the innominate and left common carotid arteries, followed by thoracic endovascular aortic repair (TEVAR). Results : The two-staged procedure was successfully completed in two patients without any significant complication. The postoperative course was uneventful for both patients. Conclusion Two-staged aortic repair in patients refusing blood transfusion can avoid circulatory arrest requiring deep hypothermia so as to reduce the risk of coagulopathy and blood loss.

  PublisherDOI

• VAD Remote Patient Monitoring (RPM): A Readmission Review

  The Journal of Heart and Lung Transplantation · 2024-04-01

  reviewOpen accessSenior author
  PublisherOA PDFDOI

• RESULTS FROM THE CLIP (CLINICAL PREDICTORS OF AORTIC PARAVALULAR LEAK) STUDY: LEFT ATRIAL VOLUME INDEX, LEFT VENTRICULAR MASS AND DENSITY PRIOR TO TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) ARE CLINICAL PREDICTORS OF PARAVALVULAR LEAK SEVERITY

  Journal of the American College of Cardiology · 2024-04-01

  article
  PublisherDOI

• Intracardiac Thrombus Associated With DeVega Tricuspid Valve Repair Following Heart Transplantation

  JACC Case Reports · 2024-08-01

  articleOpen access

  Intracardiac thrombus is a rare but treatable complication following DeVega tricuspid annuloplasty in the setting of orthotopic heart transplantation. Consistent imaging in the post-transplantation period is therefore essential for early identification and management of thromboembolic complications.

  PublisherDOI

• Abstract 4142993: Myocardial Performance Score: A Novel Marker of Cardiac Power and Efficiency for Prognostication of Advanced Heart Failure

  Circulation · 2024-11-12

  article

  Introduction: Assessment of invasive hemodynamics is a critical aspect of heart failure (HF) management influencing treatment decisions. However, standard metrics including intracardiac filling pressures and cardiac output do not consistently predict clinical outcomes. The myocardial performance score (MPS) is a novel hemodynamic parameter that combines myocardial power and efficiency into a single variable. We aimed to evaluate the prognostic significance of MPS and assess whether it can improve risk stratification compared to traditional measures. Methods: All patients who underwent isolated right heart catheterization for chronic, or acute on chronic HF between 2013-2019 at our institution were retrospectively analyzed. MPS is calculated as [aortic pulsatility index (API) x cardiac power output (CPO)]/2. The primary outcome was a composite endpoint of death or need for left ventricular assist device or heart transplant over a two-year period. MPS thresholds of 0.5 and 1.0 were selected from prior analyses showing declining efficiency less than 0.5 in addition to balanced power and efficiency greater than 1.0. Kaplan-Meier curves were calculated with statistical significance determined by log-rank tests. Results: A total of 709 patients (60±14 years; 54% male) were included, of which 102 (14%) had an MPS<0.5, 169 (24%) had an MPS between 0.5-1.0, and 438 (62%) had an MPS≥1.0. Of the 607 patients with an MPS≥0.5, 379 (62%) demonstrated freedom from the composite endpoint compared to 37 (36%) patients with an MPS<0.5 (p<0.0001). An intermediate MPS (0.5≤MPS<1.0) conveyed significantly greater freedom compared to patients with a low MPS<0.5 (57% vs 36%; p<0.001), yet lower freedom compared to those with a high MPS≥1.0 (57% vs. 66%, p<0.05). An MPS<0.5 demonstrated superior risk stratification with an odds ratio for the composite endpoint at two years of 3.1 compared to 1.8 for pulmonary capillary wedge pressure>15 mmHg and cardiac index<2.0 L/min/m 2 estimated by Fick equation or thermodilution (Figure). Conclusions: MPS is a novel, advanced hemodynamic measurement that outperforms current invasive hemodynamic parameters in accurately predicting long-term clinical outcomes in all patients with heart failure.

  PublisherDOI

Recent grants

• NIH Grant P01AI040160

  NIH · $2.8M · 2002

Frequent coauthors

• Nir Uriel

  Columbia University Irving Medical Center

  278 shared

• Takeyoshi Ota

  University of Chicago

  202 shared

• G. Sayer

  161 shared

• T. Song

  138 shared

• Gene Kim

  138 shared

• Teruhiko Imamura

  University of Toyama

  128 shared

• J. Raikhelkar

  Columbia University Irving Medical Center

  116 shared

• D. Rodgers

  University of Chicago

  102 shared

Awards & honors

• New York-Presbyterian/Columbia University Medical Center Fel…
• American Association for Thoracic Surgery (AATS) Expert Cons…